Pharmion Preps For MDS Competition; Vidaza Dosing Under Study
Executive Summary
Pharmion is testing more convenient dosing schedules for its myelodysplastic syndromes drug Vidaza (azacitidine) ahead of potential market entry of competitors in the fall